Chardan Capital issued their FY2025 earnings per share estimates for Immuneering in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst G. Livshits ...

Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report report ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

Cambridge, USA-based clinical-stage oncology company Immuneering (Nasdaq: IMRX) announced the appointment of Dr Igor ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Ph ...

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Hurco Cos (HURC) is expected to report for 1Q. Immuneering Corp (IMRX) is expected to report $-0.30 for 4Q. International Tower Hill Mines Ltd (ITH.T,THM) is expected to report for 4Q. Ivanhoe ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...